Last reviewed · How we verify
Sprycel Dasatinib tablet
At a glance
| Generic name | Sprycel Dasatinib tablet |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects (PHASE2, PHASE3)
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (PHASE3)
- Dasatinib for HIV-1 Reservoir Reduction (PHASE1)
- Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease (PHASE1, PHASE2)
- ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase (PHASE2)
- Senolytics to Improve Osteoporosis Therapy (PHASE2)
- Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment (PHASE2)
- A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sprycel Dasatinib tablet CI brief — competitive landscape report
- Sprycel Dasatinib tablet updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI